4893 items matching your search terms.

Culturally and linguistically diverse patient participation in glioma research

Lwin, Z. Broom, A. Cosman, R. Livingstone, A. Sawkins, K. Good, P. Kirby, E. Koh, E.S. Hovey, E. on behalf of the COGNO CALD working group,
NEURO-ONCOLOGY PRACTICE, 2014     DOI:10.1093/nop/npu009

Methylated glutathione s-transferase 1 as a potential plasma epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer

Mahon, K. Qu, W Devaney, J Paul, C Castillo, L. Chatfield, M. Boyer, M Stockler, M Marx, G. Gurney, H Mallesara, G. Molloy, P Horvath, L. Clark, S.

Methylated glutathione s-transferase 1 as a potential plasma epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer

Mahon, KL Qu, W Devaney, J Paul, C Castillo, L Wykes, R Chatfield, MD Boyer, MJ Stockler, MR Marx, GM Gurney, H Gowda GMH Molloy, P Horvath, L Clark, SJ PRIMe Consortium,

Circulating microRNAs associated with docetaxel-resistant castration-resistant prostate cancer

Mahon, K.L. Chiam, K Lee, B. Y. Nguyen, Q. Boyer, M.J. Stockler, M Pavlakis, M. Marx, G. Mallesara, G. Gurney, H Clark, S. Swarbrick, A. Daly, R. Horvath, L.

Methylated glutathione s-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer

Mahon, K. L. Qu, W. Devaney, J. Paul, C. Castillo, L. Wykes, R. J. Chatfield, M. D. Boyer, M. J. Stockler, M. R. Marx, G. Gurney, H. Mallesara, G. Molloy, P. L. Horvath, L. G. Clark, S. J. Prime Consortium,
BRITISH JOURNAL OF CANCER, 2014     DOI:10.1038/bjc.2014.463

Trophoblastic disease review for diagnosis and management a joint report from the international society for the study of trophoblastic disease, european organisation for the treatment of trophoblastic disease, and the gynecologic cancer intergroup

Mangili, G. Lorusso, D. Brown, J. Pfisterer, J. Massuger, L. Vaughan, M. Ngan, H. Y. S. Golfier, F. Sekharan, P. K. Charry, R. C. Poveda, A. Kim, J. W. Xiang, Y. Berkowtiz, R. Seckl, M. J.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014     DOI:10.1097/IGC.0000000000000294

Letter to the editor

Marschner, I.C.
BIOSTATISTICS, 2014     DOI:10.1093/biostatistics/kxu025

Combinatorial EM algorithms

Marschner, I.C.

Elevated circulation levels of an antiangiogenic SERPIN in patients with diabetic microvascular complications impair wound healing through suppression of Wnt signaling

McBride, J. D. Jenkins, A. J. Liu, X. Zhang, B. Lee, K. Berry, W. L. Janknecht, R. Griffin, C. T. Aston, C. E. Lyons, T. J. Tomasek, J. J. Ma, J. X.
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2014     DOI:10.1038/jid.2014.40

Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem)

McCarthy, N. Boyle, F. Zdenkowski, N. Bull, J. Leong, E. Simpson, A. Kannourakis, G. Francis, P. A. Chirgwin, J. Abdi, E. Gebski, V. Veillard, A. S. Zannino, D. Wilcken, N. Reaby, L. Lindsay, D. F. Badger, H. D. Forbes, J. F. Australia New Zealand Breast Cancer Trials Group,
BREAST, 2014     DOI:10.1016/j.breast.2013.12.001

Integrating universal consent for biobanking and health data collection within clinical pathways in NSW: the BSN Consent project

Meagher, N.S. Dean, Sally Koegelenberg, Amanda M. Goode, Susan Caruso, Lena Pillai, Ussha Marsh, Deborah J. Brown, S. Yip, S. Walczak, Adam Kench, J. G. Horvath, L. Nielsen, Sarah Scott, R. Hawkins, Nicholas J.

Final results from QUASAR2, a multicentre, international randomised phase III trial of capecitabine ± bevacizumab in the adjuvant setting of stage II/III colorectal cancer

Midgley, RS Love, S Tomlinson, I Johnstone, E Scudder, C Pearson, SR Julier, P Domingo, E Church, D Pezzela, F Hu, J Segelov, E Weaver, A Kerr, DJ

A phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: Outback (ANZGOG0902/GOG0274/RTOG1174)

Mileshkin, LR Narayan, K Moore, KN Moore, KN Rischin, D King, M Kolodziej, I Martyn, J Friedlander, M Quinn, M Small, W Thomas, G Fyles, AW Gebski, V Stockler, M ANZGOG, GOG, cRTOG,

PARAGON—phase II study of aromatase inhibitors in women with potentially hormone responsive recurrent/metastatic gynaecological neoplasms: ANZGOG 0903

Mileshkin, L. Sjoquist, K.M. Sommeijer, D. W. Cannan, D. Martyn, J. Gillies, K. O'Connell, R. L. Gebski, V. Sykes, P. Blomfield, P. Beale, P. Quinn, M. Lombard, J. Hadley, A. Grant, P. Antill, Y. Stockler, M. Amant, F. Edmondson, R.J. Friedlander, M.

Dacomitinib vs placebo in heavily pre-treated advanced NSCLC: the NCIC CTG, ALTG, NCI Naples BR.26 trial

Millward, M Boyer, M Sasidharan R Ganju, V Links, M Briggs, P Goh, J Brown, M. John, T Hui, R Lewis, C. R. Gunawardana, D Tsobanis, E Chan, MMK Ellis, P Ding, K Bradbury, PA Goss, GC Stockler, M